DrugPatentWatch Database Preview
Phentolamine mesylate - Generic Drug Details
What are the generic sources for phentolamine mesylate and what is the scope of phentolamine mesylate patent protection?
Phentolamine mesylate
is the generic ingredient in three branded drugs marketed by Septodont Holding, Precision Dose Inc, West-ward Pharms Int, and Novartis, and is included in four NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.There are four drug master file entries for phentolamine mesylate. Four suppliers are listed for this compound.
Summary for phentolamine mesylate
| US Patents: | 5 |
| Tradenames: | 3 |
| Applicants: | 4 |
| NDAs: | 4 |
| Drug Master File Entries: | 4 |
| Suppliers / Packagers: | 4 |
| Bulk Api Vendors: | 72 |
| Clinical Trials: | 6 |
| Patent Applications: | 1,185 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | phentolamine mesylate at DailyMed |
Pharmacology for phentolamine mesylate
| Drug Class | alpha-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists |
Medical Subject Heading (MeSH) Categories for phentolamine mesylate
Synonyms for phentolamine mesylate
| 134P201 |
| 2-[N-(m-Hydroxyphenyl)-p-toluidinomethyl]imidazoline Methanesulfonate |
| 2-[N-(m-Hydroxyphenyl)-p-toluidinomethyl]imidazoline, methanesulfonate |
| 3-[(2-imidazolin-2-ylmethyl)(4-methylphenyl)amino]phenol, methanesulfonic acid |
| 3-[[(4,5-Dihydro-1H-imidazol-2- yl)methyl](4-methylphenyl)-amino]phenol mesylate |
| 3-[[(4,5-Dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)-amino]phenol mesylate |
| 3-[4,5-dihydro-1H-imidazol-2-ylmethyl-(4-methylphenyl)amino]phenol; methanesulfonic acid |
| 3-[N-(2-Imidazolin-2-ylmethyl)-p-toluidino]phenol methanesulphonate |
| 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methyl-anilino]phenol; methanesulfonic acid |
| 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol; methanesulfonic acid |
| 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol;methanesulfonic acid |
| 4CA-1013 |
| 50-60-2 (Parent) |
| 65-28-1 |
| A828197 |
| A835046 |
| AB0014005 |
| AB2000443 |
| AC-7472 |
| AC1L3M27 |
| AKOS007930193 |
| AN-8957 |
| AS-13800 |
| BC200362 |
| C17H19N3O.CH4O3S |
| C18H23N3O4S |
| CCG-222286 |
| CCRIS 9022 |
| CHEMBL1200873 |
| CPD000059054 |
| CS-2419 |
| CTK8G2357 |
| D00509 |
| DR002120 |
| DTXSID60215315 |
| EINECS 200-604-6 |
| EU-0100982 |
| FT-0603267 |
| HE375279 |
| HMS2233A24 |
| HMS3263E05 |
| HMS3373D03 |
| HMS3655B13 |
| HY-B0362A |
| I14-0396 |
| J10339 |
| K062 |
| KS-00000XQY |
| Lopac-P-7561 |
| LP00982 |
| LS-104726 |
| m-(N-(2-Imidazolin-2-ylmethyl)-p-toluidino)phenol monomethanesulfonate (salt) |
| MCULE-3770473461 |
| METHANESULFONIC ACID; PHENTOLAMINE |
| MFCD00134201 |
| MLS000069487 |
| MLS001076484 |
| MolPort-003-959-154 |
| NCGC00016195-01 |
| NCGC00016195-02 |
| NCGC00094282-01 |
| NCGC00261667-01 |
| NV-101 |
| Opera_ID_1599 |
| OraVerse |
| P 7561 |
| P1985 |
| Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-, monomethanesulfonate (salt) |
| Phenol, m-(N-(2-imidazolin-2-ylmethyl)-p-toluidino)-, monomethanesulfonate (salt) |
| Phentolamine (mesylate) |
| phentolamine mesilate |
| Phentolamine mesilate (JAN/INN) |
| Phentolamine mesilate [INN:BAN] |
| Phentolamine mesilate for system suitability, European Pharmacopoeia (EP) Reference Standard |
| Phentolamine mesilate, European Pharmacopoeia (EP) Reference Standard |
| Phentolamine mesylate (USP) |
| Phentolamine mesylate [USP] |
| Phentolamine Mesylate, pharmaceutical secondary standard; traceable to USP, PhEur |
| Phentolamine mesylate, United States Pharmacopeia (USP) Reference Standard |
| Phentolamine methanesulfonate |
| Phentolamine methanesulfonate salt |
| Phentolamine methanesulfonate salt, >=98% (TLC), powder |
| Phentolamine methanesulphonate |
| REGID_for_CID_91430 |
| Regitin mesylate |
| Regitin methanesulphonate |
| Regitine (TN) |
| Regitine mesylate |
| Regitine methanesulfonate |
| s2038 |
| SAM002703130 |
| SCHEMBL40852 |
| SMR000059054 |
| SR-01000000055 |
| SR-01000000055-3 |
| ST057364 |
| Tox21_500982 |
| UNII-Y7543E5K9T |
| Vasofem |
| Vasomax |
| VZ33629 |
| W-104799 |
| Y7543E5K9T |
| Z-Max |
US Patents and Regulatory Information for phentolamine mesylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Novartis | REGITINE | phentolamine mesylate | INJECTABLE;INJECTION | 008278-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Precision Dose Inc | PHENTOLAMINE MESYLATE | phentolamine mesylate | INJECTABLE;INJECTION | 207686-001 | Jul 14, 2017 | AP | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| West-ward Pharms Int | PHENTOLAMINE MESYLATE | phentolamine mesylate | INJECTABLE;INJECTION | 040235-001 | Mar 11, 1998 | AP | RX | No | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for phentolamine mesylate
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Australia | 2005211689 | ➤ Sign Up |
| Mexico | PA04012507 | ➤ Sign Up |
| Spain | 2281418 | ➤ Sign Up |
| Japan | 4787977 | ➤ Sign Up |
| Portugal | 1280531 | ➤ Sign Up |
| Germany | 60126265 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Follow DrugPatentWatch: